Générations et estroprogestatifs, chronique d’une catastrophe annoncée - 06/07/13
| pagine | 3 |
| Iconografia | 0 |
| Video | 0 |
| Altro | 0 |
Riassunto |
Apparus à la fin des années 1990, les progestatifs de 3e génération semblaient présenter un profil pharmacologique intéressant.
Dès 1995, en Angleterre, des données soulignent qu’ils augmenteraient le risque thromboembolique. En France, la polémique est relancée récemment, suite au dépôt d’une plainte contre un laboratoire pharmaceutique.
Si ce risque est en réalité très rare, il pourrait nous permettre de repenser la prescription de la contraception.
Il testo completo di questo articolo è disponibile in PDF.Abstract |
When they appeared at the end of the 1990s, 3rd generation progesterone pills seemed to present an interesting pharmacological profile. As early as 1995, in the UK, data suggested that they might increase the risk of venous thromboembolism. In France, the controversy has been recently revived, following legal action taken against a pharmaceutical company. While the risk is in reality very low, it may nevertheless be worthwhile reconsidering how contraceptives are prescribed.
Il testo completo di questo articolo è disponibile in PDF.Mots clés : Contraception, Estroprogestatif, Génération, Pilule, Prescription, Risque thromboembolique
Keywords : Contraception, Combined oral pill, Generation, Pill, Prescription, Risk of venous thromboembolism
Mappa
Vol 12 - N° 103
P. 8-10 - luglio 2013 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?

